ESP Block Versus Wound Infiltration for Laminectomy
Launched by UNIVERSITY OF PADOVA · Feb 26, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to manage pain for people having spinal surgery called a laminectomy. The goal is to find out if a newer pain relief method called the Erector Spinae Plane Block (ESPB), which uses an ultrasound-guided injection near the spine, works better than simply injecting pain medicine directly into the surgical wound. Managing pain well after spinal surgery is very important because it helps patients move sooner, recover faster, and lowers the risk of long-term pain and other complications.
People who are 65 years or older and are scheduled for a one or two-level laminectomy may be eligible to join this study. However, those with allergies to local anesthetics, certain health problems like serious heart, kidney, or liver disease, bleeding disorders, infections, or who have recently used alcohol or drugs won’t be able to participate. If you join, you can expect to receive either the ESPB injection or wound infiltration during surgery, and the researchers will monitor your pain levels and recovery afterward. This study could help improve pain control methods for future patients undergoing spinal surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -Planned 1 or 2 level surgical laminectomy
- Exclusion Criteria:
- • Allergy to local anesthetics
- • Refusal of consent
- • Uncompensated cardiopathies, nephropathies, liver disease or peripheral neuropathies
- • Hemopathies that predispose to bleeding
- • Gastrointestinal ulcer or bleeding
- • Local infection
- • Psychiatric or neurological disorders (except those attributed to primary disease for which intervention is planned) History of abuse (or use in the 24 hours prior to surgery) Alcohol addiction ASA \> 3
About University Of Padova
The University of Padova, a prestigious research institution in Italy, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university fosters an environment conducive to the development of novel therapies and treatment modalities. Its commitment to ethical standards, patient safety, and scientific rigor ensures that all clinical trials are conducted with the highest level of integrity. Through these initiatives, the University of Padova aims to contribute significantly to the global medical community and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Padova, Veneto, Italy
Patients applied
Trial Officials
Federico Geraldini, MD
Principal Investigator
University Hospital of Padova
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials